<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head>


<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><title>Untitled Document</title>


<style>
body {
	margin:0;
}
</style></head><body>
    <table width="550px" cellpadding="0" cellspacing="0">
        <tbody>
            <tr>
                <td>
                    <img src="images/spacer.gif" height="20" width="25" />
                </td>
                <td height="15">
                    <font color="#000000" face="arial, sans-serif" size="1">Is this e-mail not displaying correctly? <a href="#" style="color: rgb(0, 103, 177);">View this e-mail in your browser</a>.</font>
                </td>
            </tr>
        </tbody>
    </table>

    <table cellpadding="0" cellspacing="0" width="550">
        <!--BEGIN HEADER-->
        <tbody><tr>
            <td>
                <table cellpadding="0" cellspacing="0">
                    <tbody><tr>
                        <td>
                            <img src="images/header1.jpg" />
                        </td>
                        <td valign="bottom">
                            <font color="#00aa86" face="arial, sans-serif" size="4"><strong><em>&nbsp;&nbsp;ZYLET<sup style="font-size: 10px; line-height: 0pt; vertical-align: 6px;">®</sup>: RELIEF TO<br />&nbsp;THE RESCUE FOR THE<br />TREATMENT OF BLEPHARITIS</em></strong></font>
                        </td>
                        <td>
                            <img src="images/logo_zylet_header.jpg" alt="Zylet Logo" />
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <img src="images/header2.jpg" />
                        </td>
                        <td>
                            <img src="images/header3.jpg" />
                        </td>
                        <td>
                            <img src="images/header4.jpg" />
                        </td>
                    </tr>
                </tbody></table>
            </td>
        </tr><!--END HEADER-->

        <tr>
            <td align="center" height="25" valign="center">
                <font color="#00aa86" face="arial, sans-serif" size="2"><strong><em>Visit <a href="http://www.BauschSampleVault.com" style="color: rgb(0, 170, 134);">www.BauschSampleVault.com</a> to order FREE ZYLET<sup style="font-size: 8px; line-height: 0pt; vertical-align: 4px;">®</sup> samples<br />for your patients.</em></strong></font>
            </td>
        </tr>

        <!--BEGIN MAIN IMAGE/GRAPHIC-->
        <tr>
            <td>
                <table cellpadding="2" cellspacing="0">
                    <tbody><tr>
                        <td width="20">
                            <img src="images/spacer.gif" height-="" 10px="" width="10" />
                        </td>
                        <td>
                            <table bgcolor="#f2f6d5" cellpadding="0" cellspacing="0" width="500">
                                <tbody><tr>
                                    <td style="" valign="top" width="164">
                                        <img src="images/eye.jpg" width="156" height="151" alt="Eye Image" />
                                    </td>
                                    <td style="border-left: medium none;" width="340">
                                        <table cellpadding="0">
                                            <tbody><tr>
                                                <td height="18" valign="top">
                                                    <font color="#0067b1" face="arial, sans-serif" size="2"><strong>Treat the signs of blepharitis with ZYLET<sup style="font-size: 8px; line-height: 0pt; vertical-align: 4px;">®</sup></strong></font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td height="42" valign="top">
                                                    <font color="#000000" face="arial, sans-serif" size="2">
                                                        ZYLET<sup style="font-size: 8px; line-height: 0pt; vertical-align: 4px;">®</sup>  effectively reduced these signs of blepharitis by approximately 70%<sup style="font-size: 8px; line-height: 0; vertical-align: 4px">1-3</sup>:
                                                    </font>
                                                    <br />
                                                        <font color="#0067b1">•</font> Hyperemia<br />
                                                        <font color="#0067b1">•</font> Scaling or crusting<br />
                                                        <font color="#0067b1">•</font> Margin hypertrophy
                                                    </font><br />
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                    <font color="#000000" face="arial, sans-serif" size="1"><strong>Study design:</strong>
A parallel-group, double-masked, randomized, prospective study
involving 17 independent centers with 276 healthy adult volunteers who
were randomized to ZYLET<sup style="font-size: 7px; line-height: 0pt; vertical-align: 2px;">®</sup> (n=138) or TobraDex (n=138) administered 4 times daily for 14 days.<sup style="font-size: 6px; line-height: 0pt; vertical-align: 2px;">1</sup></font>
                                                </td>
                                            </tr>
                                        </tbody></table>
                                    </td>
                                </tr>
                            </tbody></table>
                        </td>
                        <td><br />
</td>
                    </tr>
                </tbody></table>
            </td>
        </tr><!--END MAIN IMAGE/GRAPHIC-->
        <!--BEGIN ISI-->
        <tr>
            <td>
                <table cellpadding="0" cellspacing="0">
                    <tbody><tr>
                        <td width="25">
                            <img src="images/spacer.gif" width="25" />
                        </td>
                        <td>
                            <table cellpadding="1" cellspacing="1">
                                <tbody><tr>
                                    <td>
                                        <font color="#00aa86" face="arial, sans-serif" size="1"><strong>Indications and Usage</strong></font>
                                    </td>
                                </tr>
                                <tr>
                                    <td>
                                        <table cellpadding="0" cellspacing="0">
                                            <tbody><tr>
                                                <td valign="top" width="10">
                                                    •
                                                </td>
                                                <td>
                                                    <font color="#000000" face="arial, sans-serif" size="1">
                                                        ZYLET<sup style="font-size: 8px; line-height: 0pt; vertical-align: 2px;">®</sup>
                                                        is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

                                                        Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.

                                                        The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

                                                        The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens:
                                                        Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

                                                    </font>
                                                </td>
                                            </tr>
                                        </tbody></table>
                                    </td>
                                </tr>
                            </tbody></table>
                            <table cellpadding="1" cellspacing="1">
                                <tbody><tr>
                                    <td>
                                        <font color="#00aa86" face="arial, sans-serif" size="1"><strong>Important Risk Information</strong></font>
                                    </td>
                                </tr>
                                <tr>
                                    <td>
                                        <table cellpadding="0" cellspacing="0">
                                            <tbody><tr>
                                                <td valign="top" width="10">
                                                    •
                                                </td>
                                                <td>
                                                    <font color="#000000" face="arial, sans-serif" size="1">Zylet
is contraindicated in most viral diseases of the cornea and
conjunctiva, including epithelial herpes simplex keratitis (dendritic
keratitis), vaccinia, and varicella, and also in mycobacterial
infections of the eye and fungal diseases of ocular structures.
                                                    </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td valign="top" width="10">
                                                    •
                                                </td>
                                                <td>
                                                    <font color="#000000" face="arial, sans-serif" size="1">Prolonged
use of corticosteroids may result in glaucoma with damage to the optic
nerve, and defects in visual acuity and fields of vision. Steroids
should be used with caution in the presence of glaucoma. If this
product is used for 10 days or longer, intraocular pressure should be
monitored. </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td valign="top" width="10">
                                                    •
                                                </td>
                                                <td>
                                                    <font color="#000000" face="arial, sans-serif" size="1">
Use of corticosteroids may result in posterior subcapsular cataract
formation. </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td valign="top" width="10">
                                                    •
                                                </td>
                                                <td>
                                                    <font color="#000000" face="arial, sans-serif" size="1">The
use of steroids after cataract surgery may delay healing and increase
the incidence of bleb formation. In those diseases causing thinning of
the cornea or sclera, perforations have been known to occur with the
use of topical steroids. The initial prescription and renewal of the
medication order should be made by a physician only after examination
of the patient with the aid of magnification such as a slit lamp
biomicroscopy and, where appropriate, fluorescein staining. </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td valign="top" width="10">
                                                    •
                                                </td>
                                                <td>
                                                    <font color="#000000" face="arial, sans-serif" size="1">Prolonged
use of corticosteroids may suppress the host response and thus increase
the hazard of secondary ocular infections. In acute purulent
conditions, steroids may mask infection or enhance existing infections.
If signs and symptoms fail to improve after 2 days, the patient should
be re-evaluated. </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td valign="top" width="10">
                                                    •
                                                </td>
                                                <td>
                                                    <font color="#000000" face="arial, sans-serif" size="1">Employment
of corticosteroid medication in the treatment of patients with a
history of herpes simplex requires great caution. Use of ocular
steroids may prolong the course and exacerbate the severity of many
viral infections of the eye (including herpes simplex). </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td valign="top" width="10">
                                                    •
                                                </td>
                                                <td>
                                                    <font color="#000000" face="arial, sans-serif" size="1">Fungal
infections of the cornea are particularly prone to develop
coincidentally with long-term, local steroid application. Fungus
invasion must be considered in any persistent corneal ulceration where
a steroid has been used or is in use. </font>
                                                </td>
                                            </tr>
                                        </tbody></table>
                                    </td>
                                </tr>
                            </tbody></table>
                            <table cellpadding="1" cellspacing="1">
                                <tbody><tr>
                                    <td>
                                        <font color="#00aa86" face="arial, sans-serif" size="1"><strong>Adverse Reactions</strong></font>
                                    </td>
                                </tr>
                                <tr>
                                    <td>
                                        <font color="#000000" face="arial, sans-serif" size="1">Most
common adverse reactions reported in patients were injection and
superficial punctate keratitis, increased intraocular pressure, and
burning and stinging upon instillation. </font>
                                    </td>
                                </tr>
                                <tr>
                                    <td>
                                        <font color="#000000" face="arial, sans-serif" size="1">
                                            <strong>Please see complete information about ZYLET<sup style="font-size: 8px; line-height: 0pt; vertical-align: 2px;">®</sup> in the full prescribing information provided <a href="http://www.bausch.com/en/ECP/Our-Products/Rx-Pharmaceuticals/Rx-Pharmaceuticals-ECP/%7E/media/Files/Package-Inserts/Pharma/Zylet-package-insert.ashx" style="color: rgb(0, 103, 177);">here</a>.</strong>
                                        </font>
                                    </td>
                                </tr>
                                    <!-- References -->
                                    <tr>
                                        <td>
                                            <font face="arial, sans-serif" size="1" color="#000000">
                                                <strong>References:</strong>
                                            </font>
                                            <br />&nbsp;
                                            <font face="arial, sans-serif" size="1" color="#000000">
                                                <strong>1</strong>. White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. <em>Curr Med Res Opin</em>. 2008;24(1):287-296.
                                            </font>
                                            <br />&nbsp;
                                            <font face="arial, sans-serif" size="1" color="#000000">
                                                <strong>2</strong>. Chen M, Gong L, Sun X. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. <em>Curr Med Res Opin</em>. 201. ;28(3):385-94. doi: 10.1185/03007995.2012.659723. Epub 2012 Feb 7.
                                            </font>
                                            <br />&nbsp;
                                            <font face="arial, sans-serif" size="1" color="#000000">
                                                <strong>3</strong>. Data on file, Bausch &amp; Lomb Incorporated.
                                            </font>
                                            <br />&nbsp;
                                        </td>
                                    </tr>
                                    <!-- End of References -->

                            </tbody></table>
                            <!-- END ISI -->

                            <!--BEGIN FOOTER-->
                            <table cellpadding="1" cellspacing="1">
                                <tbody><tr>
                                    <td valign="top" width="351">
                                        <img src="images/logo_bausch_lomb.jpg" alt="Bausch &amp; Lomb Logo" /><br />
                                        <font color="#000000" face="arial, sans-serif" size="1">
                                            ZYLET is a registered trademark of Bausch &amp; Lomb Incorporated and its affiliates.<br />
                                            © 2014 Bausch &amp; Lomb Incorporated. US/ZYL/14/0004a<br /><br />
                                            If you no longer wish to receive e-mails from Bausch + Lomb<br />
                                            about ZYLET<sup style="font-size: 7px; line-height: 0pt; vertical-align: 3px;">®</sup>, <a href="http://www.bausch.com/en/ECP/EmailOptOut" style="color: rgb(0, 103, 177);">unsubscribe here</a>.
                                        </font>
                                    </td>
                                    <td valign="top">
                                        <img src="images/logo_zylet_footer.jpg" alt="Zylet Logo" />
                                    </td>
                                </tr>
                            </tbody></table><!--END FOOTER-->

                        </td>
                    </tr>
                </tbody></table>
            </td>
        </tr>

    </tbody></table>


</body></html>